PerkinElmer (PKI) Shares Sold by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. reduced its stake in PerkinElmer (NYSE:PKI) by 8.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,880 shares of the medical research company’s stock after selling 1,500 shares during the quarter. Guyasuta Investment Advisors Inc.’s holdings in PerkinElmer were worth $1,202,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of PerkinElmer by 3.2% in the 4th quarter. BlackRock Inc. now owns 6,260,111 shares of the medical research company’s stock valued at $457,740,000 after purchasing an additional 195,851 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of PerkinElmer by 4.9% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,191,284 shares of the medical research company’s stock valued at $241,644,000 after purchasing an additional 148,944 shares during the last quarter. Geode Capital Management LLC raised its position in shares of PerkinElmer by 5.9% in the 4th quarter. Geode Capital Management LLC now owns 1,263,958 shares of the medical research company’s stock valued at $92,282,000 after purchasing an additional 70,219 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of PerkinElmer by 8.0% in the 4th quarter. Bank of New York Mellon Corp now owns 1,007,210 shares of the medical research company’s stock valued at $73,647,000 after purchasing an additional 74,735 shares during the last quarter. Finally, Westwood Holdings Group Inc. raised its position in shares of PerkinElmer by 3.1% in the 4th quarter. Westwood Holdings Group Inc. now owns 841,817 shares of the medical research company’s stock valued at $61,553,000 after purchasing an additional 25,524 shares during the last quarter. 91.81% of the stock is owned by hedge funds and other institutional investors.

PerkinElmer opened at $75.47 on Friday, MarketBeat reports. The company has a quick ratio of 0.93, a current ratio of 1.33 and a debt-to-equity ratio of 0.73. The company has a market cap of $8.35 billion, a PE ratio of 25.16, a PEG ratio of 1.73 and a beta of 0.84. PerkinElmer has a 1-year low of $61.50 and a 1-year high of $84.49.

PerkinElmer (NYSE:PKI) last posted its earnings results on Monday, April 30th. The medical research company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.02. The firm had revenue of $644.00 million during the quarter, compared to analyst estimates of $618.97 million. PerkinElmer had a net margin of 11.73% and a return on equity of 13.26%. The business’s quarterly revenue was up 0 on a year-over-year basis. During the same period in the previous year, the firm earned $0.55 EPS. analysts expect that PerkinElmer will post 3.61 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, August 10th. Stockholders of record on Friday, July 20th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.37%. The ex-dividend date of this dividend is Thursday, July 19th. PerkinElmer’s dividend payout ratio (DPR) is 9.66%.

A number of research firms have issued reports on PKI. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $83.00 price target for the company in a research report on Thursday. ValuEngine lowered shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Wednesday, May 2nd. Morgan Stanley raised their price target on shares of PerkinElmer from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 1st. Bank of America reduced their price target on shares of PerkinElmer from $86.00 to $83.00 and set a “hold” rating for the company in a research report on Tuesday, May 1st. Finally, Robert W. Baird reduced their price target on shares of PerkinElmer from $88.00 to $82.00 and set an “outperform” rating for the company in a research report on Tuesday, May 1st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. PerkinElmer presently has an average rating of “Hold” and an average target price of $77.36.

In other news, insider Frank Anders Wilson sold 103,656 shares of PerkinElmer stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $73.94, for a total transaction of $7,664,324.64. Following the completion of the transaction, the insider now directly owns 93,624 shares of the company’s stock, valued at approximately $6,922,558.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Daniel R. Tereau sold 1,156 shares of PerkinElmer stock in a transaction that occurred on Wednesday, April 18th. The shares were sold at an average price of $77.00, for a total transaction of $89,012.00. Following the transaction, the insider now directly owns 6,784 shares of the company’s stock, valued at $522,368. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply